Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dfe24ee8a88e926d7b3a4179ee7314 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
filingDate |
2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaeb68ea7d45cca481fe485655ec0007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6771ac5af6034917b908756dafbd2e7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c4e7d791d656b5b2a58647478fd840a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_079dfa499a2b391a6196bdd3784c07a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e428ec24712ccf9688a7e5031b303be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fd5ba03256cea647e3dc95f24b252b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d067fde17da1f229ebf9efc57781e5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcd8fa4475ed0121438a9e390de4e8c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd7d314310dcfd4cff02e0d789f76347 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf06dd7c157a6727dd2f1a0d760b2211 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ad8be4acf3d4a5a1877716d63a58bd9 |
publicationDate |
2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9676746-B2 |
titleOfInvention |
Crystalline forms of C21H22Cl2N4O2 |
abstract |
The present invention provides crystalline forms of a compound of formula (I): n nAlso provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11390600-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10738027-B2 |
priorityDate |
2015-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |